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WHO interim guidance on pregnancy management in the 
context of Zika virus infection
As a result of an unusual clustering of cases of 
microcephaly and Guillain-Barré syndrome, WHO 
declared the 2015–16 Zika virus outbreak in the Americas 
a “public health emergency of international concern”.1 
As part of its strategic response to the outbreak, WHO 
is leading normative work to mitigate the potential 
impact on pregnant women, newborn babies, and 
other at-risk populations. Last week, WHO launched an 
updated version of its guidance on pregnancy care in 
the context of Zika virus infection.2 The guidance covers 
recommendations for preventing maternal Zika virus 
infection, antenatal care and management of women 
with infection, and care for all pregnant women with 
possible exposure to Zika virus through residence in or 
travel to an aﬀ ected area.
Vector control is critical in substantially reducing the 
risk of maternal and fetal Zika virus infection. Therefore, 
the guidance emphasises the importance of counselling 
pregnant women about preventive measures at every 
antenatal contact. Recommended personal protection 
measures include the use of clothing that covers 
as much of the body as possible, bednets, window 
and door screens, safe repellents, and avoidance of 
unprotected sexual activity with a partner possibly 
exposed to Zika virus. In addition to recommending 
local measures to reduce vector breeding sites, the 
guidance notes the importance of addressing the 
underlying social determinants of this outbreak, and 
encourages governments to take broader steps to 
provide sustainable and equitable access to clean water, 
sanitation, and appropriate waste management.
Antenatal care in the context of Zika virus 
transmission requires speciﬁ c actions to prevent 
infection, and to identify women who might be infected 
for testing, appropriate care, and follow-up. The 
guidance recommends that Zika virus infection should 
be suspected on the basis of the common signs and 
symptoms—rash, fever, arthralgia, and conjunctivitis—
lasting 2–7 days, and conﬁ rmed using RT-PCR detection 
of Zika virus RNA in blood (or urine) samples collected 
within 1 week of symptoms or by serology for Zika-
virus-speciﬁ c IgM thereafter. As there is currently 
no speciﬁ c therapy for Zika virus infection, only 
symptomatic treatment is recommended whenever 
there are symptoms. 
The guidance includes decision charts for testing and 
care of pregnant women residing in areas with ongoing 
Zika virus transmission, and for pregnant women with 
a history of recent travel to such areas. Testing for Zika 
virus infection is recommended for pregnant women 
presenting with (or reporting) signs and symptoms or 
those with ultrasound ﬁ ndings of fetal abnormalities 
at any time during pregnancy. WHO does not at this 
time recommend universal testing of pregnant women 
for Zika virus. Rather, it reinforces the need to oﬀ er 
all women early ultrasound examinations, including 
a fetal anomaly scan at 18–20 weeks to accurately 
date the pregnancy and evaluate fetal anatomy. 
The guidance points to a broader spectrum of fetal 
abnormalities that should raise a suspicion of congenital 
Zika virus infection. These include microcephaly, 
ventriculomegaly, intracranial calciﬁ cations, cerebral 
atrophy, callosal dysgenesis, micro-ophthalmia, eye 
calciﬁ cation, growth restriction, and even fetal death.3,4
As shown in the ﬁ gure, Zika-virus-related fetal 
abnormalities should be suspected in pregnant women 
with ultrasound evidence of fetal abnormalities and a 
positive or inconclusive Zika virus test. Pregnant women 
with a history of symptoms, no ultrasound evidence 
of fetal abnormalities, and a negative Zika virus test 
are most likely unaﬀ ected and should continue to 
receive routine antenatal care. Pregnant women with 
abnormal ultrasound ﬁ ndings but a negative Zika virus 
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Figure: InterpretaƟ on of Zika virus test and ultrasound fi ndings in the 
context of Zika virus transmission
STORCH=syphilis, toxoplasmosis, rubella, cytomegalovirus, and herpes virus 
infections. 
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test should be suspected of having fetal abnormalities 
due to other conditions, including congenital infections 
(eg, syphilis, toxoplasmosis, rubella, cytomegalovirus, 
and herpes virus infections), and will need further 
investigations. The ﬁ nding of a positive or inconclusive 
Zika virus test but no fetal abnormalities on ultrasound 
suggests maternal infection without fetal involvement 
at the time of examination. While these women should 
continue to receive routine antenatal care, serial 
ultrasound follow-up until birth is advised. 
The management decisions for fetal abnormalities 
in the context of Zika virus infection pose serious 
challenges for settings with limited resources. 
Depending on the severity of fetal abnormalities and 
their prognosis, the guidance notes that management 
options could range from specialised antenatal care and 
serial ultrasound follow-up to monitor progression of 
the abnormalities, to a discussion of the potential next 
steps in managing the pregnancy. It recommends that 
the woman—and her partner if she so wishes—be oﬀ ered 
non-directive counselling so that, in consultation with 
her health-care provider, she can make a fully informed 
choice about further management options. For women 
who carry their pregnancy to term, health-care providers 
should oﬀ er appropriate psychosocial support to 
manage anxiety and stress5 and arrange consultations 
with a paediatrician or a paediatric neurologist, where 
possible. The guidance recommends that women who 
wish to discontinue their pregnancy should receive 
accurate information about their options to the full 
extent of the law, including harm reduction practices 
where the care desired is unavailable.6
The guidance highlights key evidence gaps, 
particularly in relation to the natural history of maternal 
and fetal Zika virus infection, vertical transmission risk, 
and interventions to reduce perinatal transmission. 
Appropriately designed studies are urgently required to 
respond to these questions. 
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